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Background: Increasing evidence suggests the safety and efficacy of mesenchymal stromal cells (MSC) as advanced
therapy medicinal products because of their immunomodulatory properties and supportive role in hematopoiesis.
Although bone marrow remains the most common source for obtaining off-the-shelf MSC, cord blood (CB) represents
an alternative source, which can be collected noninvasively and without major ethical concerns. However, the low
estimated frequency and inconsistency of successful isolation represent open challenges for the use of CB-derived
MSC in clinical trials. This study explores whether CB may represent a suitable source of MSC for clinical use and
analyzes several in vitro parameters useful to better define the quality of CB-derived MSC prior to clinical application.
Methods: CB units (n = 50) selected according to quality criteria (CB volume ≥ 20 ml, time from collection ≤ 24 h) were
cultured using a standardized procedure for CB-MSC generation. MSC were analyzed for their growth potential and
secondary colony-forming capacity. Immunophenotype and multilineage differentiation potential of culture-expanded
CB-MSC were assessed to verify MSC identity. The immunomodulatory activity at resting conditions and after
inflammatory priming (IFN-γ-1b and TNF-α for 48 hours) was explored to assess the in vitro potency of CB-MSC prior to
clinical application. Molecular karyotyping was used to assess the genetic stability after prolonged MSC expansion.
Results: We were able to isolate MSC colonies from 44% of the processed units. Our results do not support a role of
CB volume in determining the outcome of the cultures, in terms of both isolation and proliferative capacity of CB-MSC.
Particularly, we have confirmed the existence of two different CB-MSC populations named short- and long-living
(SL- and LL-) CBMSC, clearly diverging in their growth capacity and secondary colony-forming efficiency. Only LL-CBMSC
were able to expand consistently and to survive for longer periods in vitro, while preserving genetic stability. Therefore,
they may represent interesting candidates for therapeutic applications. We have also observed that LL-CBMSC were
not equally immunosuppressive, particularly after inflammatory priming and despite upregulating priming-inducible
markers.
Conclusions: This work supports the use of CB as a potential MSC source for clinical applications, remaining more
readily available compared to conventional sources. We have provided evidence that not all LL-CBMSC are equally
immunosuppressive in an inflammatory environment, suggesting the need to include the assessment of potency
among the release criteria for each CB-MSC batch intended for clinical use, at least for the treatment of immune
disorders as GvHD.* Correspondence: astori@hemato.ven.it
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Mesenchymal stromal cells (MSC) comprise a heteroge-
neous population of multipotent progenitor cells used in
clinic for their immunomodulatory properties and their
supportive role in hematopoiesis. Three main criteria
have been proposed by the International Society for
Cellular Therapy (ISCT) for MSC definition: (1) adher-
ence to plastic under standard culture conditions; (2) ex-
pression of CD105, CD73, CD90, and lack of expression
of HLA-DR, together with the hematopoietic and endo-
thelial surface markers CD14, CD45, CD34, CD11b, and
CD31; (3) in vitro differentiation potential into osteo-
cytes, chondrocytes, and adipocytes under appropriate
culture conditions [1].
MSC are potent modulators of immune responses, by
virtue of direct cell-cell contact and production of poorly
defined soluble factors [2–4]. MSC are not constitutively
inhibitory, but acquire their immunosuppressive func-
tions following priming by inflammatory cytokines,
mainly interferon gamma (IFN-γ) and tumor necrosis
factor alpha (TNF-α) [5, 6]. The inducible MSC immu-
noregulatory properties are shared by MSC from bone
marrow (BM) and other tissues, as well as by more
differentiated fibroblasts [7].
The amenability to ex vivo expansion and the immu-
nomodulatory activity of MSC have encouraged exten-
sive studies paving the way for their therapeutic use, in
the context of hematopoietic stem cell transplantation
(HSCT) and other clinical settings [8–10]. Since 2004,
the use of cryopreserved allogeneic MSC for the treat-
ment of steroid-refractory acute graft-versus-host disease
(aGvHD) has become medical practice in many coun-
tries [11, 12].
Although BM remains the most common source, MSC
can be isolated from various human tissues [13–15].
Particularly, cord blood (CB) represents an alternative
source, which can be collected noninvasively and with-
out major clinical concerns. The network of public CB
banks worldwide provides an easy-to-access system for
the use of fresh CB units for MSC generation when they
are not suitable for banking, so that CB-derived MSC
can be expanded and cryopreserved in advance with
enormous clinical advantages.
CB-MSC display peculiar morphological, differentia-
tive and trophic properties [16, 17]. Some authors
demonstrated a higher proliferative potential of CB-
MSC compared with BM- or adipose tissue-derived
MSC, together with a normal karyotype after prolonged
expansion [18–20]. More recently, the existence of dis-
tinct stromal CB populations with different perfor-
mances in vitro has been postulated, on the basis of
their proliferative potential, colony-forming efficiency,
and telomere length [21]. Fewer studies have compre-
hensively addressed the immunomodulatory propertiesof CB-MSC, exerted on several T cell subsets and NK
cells, but also through inhibition of dendritic cell
function [20, 22–25].
To date, the low estimated frequency and the incon-
sistency of successful isolation are open challenges for
the use of CB-MSC in clinical trials [26–28]. Most au-
thors over the last years have suggested that CB volume
and time from collection should be considered for a suc-
cessful CB-MSC isolation [20, 29–31]. Recent studies
have proposed efficient methods to obtain CB-MSC,
avoiding strict quality selection of the starting material.
These methods combined the traditional MNC separ-
ation or CB immunodepletion with the addition of
variable supplements or coating strategies to support
MSC growth [32, 33]. In this regard, the use of dexa-
methasone at the beginning of the culture has proven to
inhibit monocyte adhesion and support CB-MSC prolif-
eration [20, 33, 34], without inducing changes in the
subsequent differentiation potential [35].
The present study aimed at obtaining MSC from CB,
by means of an isolation procedure based on the transi-
ent use of dexamethasone as medium supplement. An
essential goal was to analyze several in vitro parameters
useful to define the quality of CB-derived MSC in view
of their clinical use. Ultimately, the immunomodulatory
function during the inflammation process was assessed




CB was collected after maternal informed consent
from the Department of Transfusion Medicine, San
Bortolo Hospital (Vicenza, Italy). CB units were col-
lected from full-term deliveries by venipuncture imme-
diately after cord clamping and before the delivery of
placenta (in utero), then stored in bags containing
30 ml of citrate phosphate dextrose (Fresenius-Kabi,
Bad Homburg vor der Höhe, Germany). Only CB units
not suitable for banking with a net volume higher than
20 ml were processed within 24 hours from the collec-
tion. Clinical information from each donor including
pregnancy details and CB parameters was prospectively
collected.
CB-MSC isolation and expansion
Mononuclear cells (MNC) were obtained by density
gradient centrifugation (Lymphoprep™, Sentinel Ch. Spa,
Milan, Italy) of whole CB diluted 1:1 with phosphate-
buffered saline (D-PBS, Sigma-Aldrich, St. Louis, MO,
USA). MNC were collected from the interphase, washed
twice with D-PBS and plated at a density of 1–2 × 106
cells/cm2 and 5–7 × 106 cells/ml in low-glucose Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented
Amati et al. Stem Cell Research & Therapy  (2017) 8:14 Page 3 of 15with 20% of fetal bovine serum (FBS) (both from Gibco,
Thermo Fisher Scientific, Waltham, MA, USA), 10-7M
dexamethasone (DEXA) (Hospira, Lake Forest, IL,
USA), 100 U/ml penicillin and 100 μg/ml streptomycin
(Sigma-Aldrich). Cells were then incubated at 37 °C in a
humidified atmosphere containing 5% CO2 and standard
O2 concentrations. One week from initial plating, non-
adherent cells were removed. Remaining cells were fed
once a week and screened for colony appearance for a
maximum of 4 weeks (see Additional file 1: Fig. S1).
DEXA was added in the culture until the detection of
MSC colonies or alternatively supplemented for only the
first week of MNC culture (n = 16 and n = 34 CB units,
respectively; see Additional file 2: Fig. S2). MSC colonies
at 80% confluence were harvested using 10 × TrypLE Se-
lect (Thermo Fisher Scientific) and subcultured at a
density of 4000 cells/cm2. Standard medium was re-
placed twice a week and proliferation patterns were
established by counting cells each week.
Growth kinetics and secondary colony-forming ability
of CB-MSC
To estimate MSC growth, cells under maintenance con-
ditions were progressively subcultured for 10–12 pas-
sages. At each subcultivation, the population doubling
(PD) was calculated as follows: PD = log10 (N)/log10 (2),
where N is the number of harvested cells/the number of
initially seeded cells. The cumulative PD (cPD) was cal-
culated adding to the PD of the passage under analysis
the PDs of the previous passages.
To evaluate the secondary colony-forming ability of
CB-MSC, 200 MSC collected at P1 were plated in dupli-
cate into 100-mm diameter culture dishes (Cellstar®,
Grainer Bio-One GmbH, Frickenhausen, Germany) for
six to seven additional passages. Standard medium was
changed weekly and after 2 weeks the cells were fixed
with 10% formalin, washed with deionized water and
stained with May-Grunwald-Giemsa for 20 minutes.
Colonies consisting of at least 30 cells were counted
under an inverted light microscope (Axiovert 40 CFL,
Zeiss, Oberkochen, Germany).
Molecular karyotyping
Molecular karyotyping of CB-MSC (n = 3) at early (P5)
and late passages (P11–13) was performed through
array-comparative genomic hybridization (array-CGH)
with CytoChip Oligo ISCA 4 × 180 K platform (Blue-
Gnome, Cambridge, UK) and Fluorescent Labelling
System (dUTP) kit (BlueGnome). High molecular weight
DNA was extracted using the QIAamp DNA Mini kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s protocol. A pool of characterized genomic DNA
(Human Genomic DNA Male and Female, Promega,
Madison, WI, USA) was used as control DNA for allexperiments. Sample and control DNA were labeled with
Cy3 and Cy5 fluorophores, using random primers.
Labeling mixes were combined and concentrated for
hybridization. Labeled DNA was resuspended with
blocking agents in hybridization buffer and applied to
the CytoChip Oligo array surfaces using the gasket
slides. Hybridization was performed in a rotating oven.
Hybridized CytoChips were washed to remove unbound
labeled DNA. A laser scanner was used to excite the hy-
bridized fluorophores and read and store the resulting
images of the hybridization. Data analysis was performed
through BlueFuse Multi for Microarrays v4.0 software-
cytochip V2 algorithm (Illumina, San Diego, CA, USA).
Quality control parameters for every experiment were
evaluated.
CB-MSC trilineage differentiation
For osteogenic and adipogenic differentiation, CB-MSC
at the end of passage 4 were seeded at a density of 4000
cells/cm2 on cell culture coverslips (Thermo Fisher
Scientific) arranged in 24-well plates (Falcon®, Corning,
Corning, NY, USA) in the presence of standard growth
medium. At 70–80% of cell confluence, the medium was
replaced with specific differentiation media, then
renewed every 3–4 days for 21 days. To induce adipo-
genic differentiation, cells were incubated using the
StemPro® Adipogenic Differentiation Kit (Thermo Fisher
Scientific), according to the manufacturer’s instructions.
The presence of intracellular lipid droplets was detected
by standard staining with Oil Red O (Diapath, Bergamo,
Italy), according to the manufacturer’s instructions. In
parallel, cells were also grown using the StemPro® Osteo-
genic Differentiation Kit (Thermo Fisher Scientific) to
induce osteogenic differentiation. The presence of cal-
cium deposits was evaluated by von Kossa staining
(Sigma-Aldrich). Cells were fixed with 10% formalin for
5 minutes at room temperature, incubated with 1% silver
nitrate solution for 15 minutes and exposed to ultravio-
let light for 2 hours. Coverslips were rinsed with distilled
water and 5% sodium thiosulfate to remove unreacted
silver. Finally, cells were counterstained with Nuclear
Fast Red Solution (Sigma-Aldrich). To induce chondro-
genesis, 25 × 104 cells were placed in a 15-ml polypropyl-
ene tube (Falcon®, Corning) and washed in order to form
a pelleted cellular micromass at the bottom of the tube.
The cell pellet was cultured in 500 μl chondrogenic
induction medium (StemPro® Chondrogenic Differenti-
ation Kit, Thermo Fisher Scientific), following the
recommendations of the manufacturer. Fresh chondro-
genic medium was added every 3–4 days. After 28 days,
the micromass was fixed, embedded in agar, cut with a
microtome and stained with Alcian Blue (Sigma-
Aldrich). Cells were counterstained with Nuclear Fast
Red Solution.
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chain reaction (qRT-PCR)
Total RNA was extracted using RNeasy Plus Mini Kit
(Qiagen) following the manufacturer’s instructions and
its quality and quantity were determined using a Nano-
drop UV-VIS spectrophotometer (Thermo Fisher Scien-
tific). First-strand cDNA were synthesized from 800 ng
of total RNA in 20 μl final volume, using the iScript
cDNA synthesis kit (Bio-Rad Laboratories, Hercules,
CA, USA) according to the manufacturer’s instructions.
The mRNA expression of osteogenic markers RUNX2
and ALP, adipogeneic markers PPARG and FABP4, and
chondrogenic markers SOX9 and COLXA1 was quanti-
fied by using Sso Fast evaGreen Supermix (Bio-Rad
Laboratories) on the ABI 7500 Real-Time PCR System
(Applied Biosystems, Thermo Fisher Scientific), accord-
ing to the producer’s recommendations. Primer se-
quences are summarized in Additional file 3: Table S1.
The thermal cycling protocol involved initial denatur-
ation at 95 °C for 30 sec and was followed by 40 cycles
of denaturation at 95 °C for 5 sec and primer annealing
and elongation for 32 sec at 60 °C, with a final melting
curve analysis to test for the specificity of the product.
Data acquisition and analysis were obtained by using
SDS v1.4 software (Applied Biosystems, Thermo Fisher
Scientific). Each gene was tested in three replicates and
three independent experiments were performed. The
level of each target gene was normalized to the undif-
ferentiated control by using the 2-ΔΔCT method to
quantify the relative changes in gene expression and by
applying the efficiency correction represented by the
equation: efficiency = 10(-1/slope) -1. TBP and YWHAZ
were used as endogenous reference genes [36], pro-
vided the verification of their stability under differenti-
ation conditions (Additional file 4: Fig. S3). PCR
efficiency corrections were determined for target and
reference genes by running a standard PCR curve using
diluted cDNA.
Immunophenotypic analysis
Five color combinations of monoclonal antibodies
(mAbs) were used to identify and characterize CB-MSC
(n = 5) after passage 2 according to the expression of a
panel of markers shown in Additional file 5: Table S2. A
restricted panel was used to detect the phenotypic modi-
fications induced on MSC by inflammatory priming (see
Additional file 6: Table S3). Inflammatory priming was
performed by treating CB-MSC at 80% confluence with
10 ng/ml rh-IFN-γ-1b (Imukin, Boehringer-Ingelheim,
Ingelheim, Germany) and 15 ng/ml rh-TNF-α (R&D
Systems, Minneapolis, MN, USA) for 48 hours of culture,
as suggested by the ISCT [37].
About 105 cells were stained for 15 minutes at room
temperature in the dark with the specific combination ofmAbs. Appropriate fluorescence-minus-one (FMO) and
unstained controls were used to determine the level of
unspecific binding. At least 10,000 events were acquired
on a Cytomics FC500 cytometer (Beckman Coulter,
Brea, CA, USA). Data were analyzed by Kaluza software
2.1 version (Beckman Coulter). Expression of individual
markers was recorded as the ratio of median fluores-
cence intensity obtained for each marker and its negative
or FMO control in the corresponding fluorescence
detector (rMFI).
Immunomodulation assay
Peripheral blood mononuclear cells (PBMC) were ob-
tained from buffy coats of healthy donors after informed
consent. PBMC were isolated by density gradient centri-
fugation and cryopreserved until use. Thawed PBMC
were suspended in RPMI 1640 (Sigma-Aldrich) supple-
mented with 10% FBS, 1 × L-glutamine (Sigma-Aldrich),
100 U/ml penicillin and 100 μg/ml streptomycin and
rested overnight at 37 °C in a humidified atmosphere
containing 5% CO2 and standard O2 concentrations.
Overnight resting allowed only a minimal monocyte ad-
hesion, as shown in Additional file 7: Fig. S4. Resting
and primed CB-MSC (n = 4), the latter stimulated for
48 hours of culture with IFN-γ-1b and TNF-α, were
seeded in 96-well flat-bottomed plates (Falcon®, Corning):
4 × 104 cells for the highest (1:0.2) PBMC:MSC ratio were
titrated to 1 × 104 to achieve the lowest (1:0.05)
PBMC:MSC ratio.
To measure proliferation, PBMC were stained with
5 μM 5,6-carboxyfluorescein diacetate succinimidyl ester
(CellTrace™ CFSE Cell Proliferation Kit, Invitrogen,
Thermo Fisher Scientific) according to the manufac-
turer’s instructions. CFSE-labeled cells were seeded on a
MSC monolayer at different PBMC:MSC ratios: 1:0.2,
1:0.1, 1:0.05 and 1:0 (no MSC treatment). Cells were
stimulated with 0.5 μg/ml of anti-CD3 antibody (Milte-
nyi Biotec, Bergisch Gladbach, Germany) and 500 UI/ml
of recombinant human interleukin-2 (rh-IL-2) (Proleu-
kin®, Novartis, Basel, Switzerland) for 6 days before
measuring the corresponding decrease in CFSE fluores-
cence by flow cytometry. For the latter, anti-human
CD45-phycoerythrin-Texas Red (ECD) (J.33 clone,
Beckman Coulter) mAb was used to assess proliferation
on gated CD45+ cells. At least 50,000 events were ac-
quired on a Cytomics FC500 cytometer. CFSE analysis
was performed by Kaluza software and proliferation was
quantified as the percentage of cells undergoing at least
one cell division.
Statistical analysis
Clinical information and CB parameters from each donor
are presented as relative frequencies or median values and
their ranges for each categorical or continuous variable
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Shapiro-Wilk tests were used to verify the normal dis-
tribution of each continuous variable. The differences
between the continuous variables were computed by
unpaired t test or Mann-Whitney U test as appropriate.
The differences between categorical variables were
computed by Fisher’s exact test. Statistical comparison
between resting and primed MSC (i.e., MSC treated or
not with inflammatory cytokines) for each MSC batch
was performed using the t test for matched pairs. Pro-
liferation data are presented as mean with SEM and
statistical significance was calculated by two-way
ANOVA. P values <0.05 were considered statistically
significant. Statistical analyses were performed using
GraphPad Prism 5.01 software (GraphPad Software
Inc., La Jolla, CA, USA).Results
CB-MSC generation
A total of 50 CB units with a median volume of 41 ml
(range 18–87 ml) and time after collection of 5.30 h
(range 2–24 h) entered this study. MSC isolation was
effective in 44% of processed units (22/50). Given the
low frequency of MSC progenitors within CB, CB-MSC
were mostly isolated as single clones, regardless of the
starting volume. MSC colonies were observed at a me-
dian of 10.5 days (range 7–20) after MNC plating, while
the first trypsinization occurred after a median of 13 days
(range 9–22), at about 80% confluence. Differences in ei-
ther the clinical features of the donors or CB parameters
were not globally found between successful and unsuc-
cessful samples, as shown in Table 1.Table 1 Comparison between donor characteristics and successful C
All samples (n = 50) MSC-p
Median time after delivery, hours (range) 5 (2–24) 5 (2–2
Median TNC × 106 (range) 696 (276–1700) 675 (3
Median MNC × 106 (range) 191 (14–615) 200 (8
CB median volume, ml (range) 41 (18–87) 43 (22
Median gestational time, days (range) 273 (259–292) 273 (2
Median mother age, years (range) 35 (26–45) 34 (29
Pluriparity 27 (54%) 11 (50
Male babies 27 (54%) 14 (63
Median baby weight, grams (range) 3390 (2430–4460) 3335
Mater/baby blood group match 26 (52%) 15 (68
Cesarean birth 14/48 (29.2%) 7/20 (




*The differences between the categorical variables were computed by the Fisher exEffect of dexamethasone exposure on CB-MSC culture
outgrowths
As first approach we cultured 16 CB units in the
presence of 10-7 M DEXA until the detection of MSC
growing colonies [34]. CB-MSC clones were isolated
from 37.5% CB units (6/16). Colonies were detected at a
median of 12.5 days from initial plating (range 8–20)
and harvested after a median of 13.5 days (range 13–22).
All samples except one reached at least five passages.
To assess whether a lower exposure to DEXA could
improve CB-MSC isolation and proliferation capability,
a second series of CB units (n = 34) was subjected to
DEXA supplementation for the first week of MNC
culture only. In this condition, MSC isolation was suc-
cessful in 47.1% units (16/34), with a median detection
and harvest time of 10 (range 7–15) and 12 days (range
9–15), respectively. All samples were capable to reach at
least five passages.
The withdrawal of DEXA after the first week of MNC
culture did not significantly modify either the efficiency
of CB-MSC isolation (p = 0.5253, Fig. 1a) or the cPD at
P5 (p = 0.0867, Fig. 1b).
CB-MSC growth characteristics
The isolated CB-MSC displayed initially a small spindle-
shape morphology and a high degree of heterogeneity,
mainly due to the contamination by osteoclast-like cells
and non-proliferating fibroblast-like cells. These contam-
inating cells that were strongly adhered to the bottom of
the flasks were eliminated by P2 passage (Fig. 2a-c).
Differences in the proliferative capacity and exhaustion
passage were observed between MSC from different
units. Overall, 1/3 of CB-derived MSC were able toB-MSC isolation
ositive isolation (n = 22) MSC-negative isolation (n = 28) p value
4) 7 (2–24) 0.799°
83–1290) 700 (276–1700) 0.662°
5–615) 191 (14-–62) 0.703°
–87) 40 (18–78) 0.323§
64–292) 275 (259-–92) 0.288°
–41) 35 (26–45) 0.799§
%) 16 (57.1%) 0.198*
.6%) 13 (46.4%) 0.264*
(2700–4460) 3405 (2430-–090) 0.674§
.2%) 11 (39.3%) 0.052*
35%) 7/28 (25%) 0.528*
nuclear cells, CB cord blood
act test
Fig. 1 Effect of dexamethasone on CB-MSC culture outgrowths.
a Effects of two different treatment regimens with DEXA (>1 wk or 1
wk, n = 16 and n = 34, respectively) on CB-MSC isolation (n = 6 and
n = 16, respectively). Gray color: positive MSC isolation. White color:
negative MSC isolation. The differences were computed by Fisher
exact test, p > 0.05. b Comparison of cumulative population doubling
(cPD) at P5 between CB-MSC isolated by adding DEXA for > 1wk or 1
wk (n = 6 and n = 15, respectively). The differences were computed by
Mann-Whitney U test, p > 0.05. Boxes extend from 25th percentile to
the 75th percentile, the middle line represents median value and the
whiskers extend from minimum to maximum values. Abbreviations:
cPD cumulative population doublings, DEXA dexamethasone, wk week
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long-term proliferative potential at least two growth
kinetics patterns were recognized. We distinguished
short- and long-living (SL- and LL-) CB-MSC based on
their lower or higher cPD, respectively (cPD cutoff = 20
at p9). LL-CBMSC displayed a constant greater growth
and longevity than SL-CB-MSC (Fig. 2d). Moreover, by
comparing the cPD at each passage, significant differ-
ences in the proliferative capacity were revealed by pas-
sage 5 (Fig. 2e).
Since the discrimination between SL- and LL-CBMSC
based on the cPD could only be done retrospectively, we
sought to identify an earlier distinctive marker, possibly
of clinical utility for the choice of the batches of CB-
MSC suitable for large-scale expansion and clinical use.
As already demonstrated, the heterogeneous proliferativepotential reflected differences in the self-renewal cap-
acity [21, 38]. By assessing the secondary colony-forming
capability of the two populations, we found that LL-
CBMSC retained greater secondary colony-forming abil-
ity compared to SL-CBMSC. Conversely, SL-CBMSC
failed to self-renew after a few passages then lost the
growth capacity earlier (Fig. 2f-g). Significant differences
were specifically observed at passage 4, albeit on a lim-
ited number of samples (Fig. 2h).
We next addressed the role of donor characteristics
and CB parameters (listed in Table 1) as discriminating
markers between LL- and SL-CBMSC. Quite surpris-
ingly, we found that the median of CB volumes of units
giving rise to SL-CBMSC was significantly higher
(51 ml, range 22–87) with respect to the volume of CB
units giving rise to LL-CBMSC (31 ml, range 27–42)
(p = 0.0388, n = 16 and n = 5, respectively, Fig. 2i).
Finally, in order to test the genetic stability of CB-
MSC after prolonged expansion, three LL-CBMSC
batches at early (P5) and late passages (P11–13) were
tested for their genomic assets through array-CGH
analysis. Results revealed that expanded CB-MSC did
not show unbalanced chromosomal rearrangements
(deletion or duplication), excluding copy number variation
constitutionally present (see Additional file 8: Fig. S5).
Multilineage differentiation
To investigate the in vitro differentiation potential of
CB-MSC from various LL donors, cells at P4 were in-
duced to differentiate down the osteogenic, adipogenic
and chondrogenic lineages, by using defined media com-
ponents and culture conditions (Fig. 3a-f ). All CB-MSC
(n = 5) demonstrated osteogenic differentiation after
3 weeks of induction. By contrast, we observed poor adi-
pogenic potential (1/5 samples) as revealed by Oil Red O
staining. When cultured under chondrogenic conditions,
cartilage-like cells with lacunae and a large amount of
cartilage extracellular matrix were observed in sections
of pellets from all samples. Parallel experiments on
SL-CBMSC confirmed the absence of dissimilarities
compared to LL-CBMSC in regard to osteogenic and
adipogenic multilineage differentiation (Additional file 9:
Fig. S6), while chondrogenic potential was not assessed
due to the difficulty to obtain a sufficient number of SL
cells for the assay.
To confirm multilineage differentiation at a molecular
level, the transcript levels of both early- and late-stage
markers of adipogenesis, osteogenesis, and chondrogenesis
were determined by means of qRT-PCR in LL-CBMSC.
Results from three independent experiments confirmed,
even with variability between MSC donors, significant up-
regulation of all mRNA transcripts involved in chondro-
genic and osteogenic MSC differentiation (p = 0.0039 for








Fig. 2 Morphology and growth characteristics of CB-MSC. a Colony of CB-MSC 10 days after initial seeding (passage 0). b Non-proliferative
fibroblast-like cells and osteoclast-like cells, the latter with very large cytoplasm and occasional multiple nuclei (passage 0). c Morphology of CB-MSC at
passage P1. Scale bars: 100 μM. d Growth patterns of CB-MSC grouped by similar cPD (cPD cutoff = 20 at P9). Black circles: LL-CBMSC; white circles: SL-
CBMSC. e Comparison of cPD between LL- (black bars) and SL- (white bars) CBMSC at each passage; the differences were computed by Mann-Whitney
U test, *p < 0.05, **p < 0.01, ***p < 0.001; data are presented as mean with SEM. f Secondary colony formation of LL-CBMSC (black circles) and SL-CBMSC
(white circles) at defined passages. g Colonies formed after plating 200 MSC in 100-mm culture dishes are shown from one representative LL- and one
SL-CBSMC (CB010 and CB019, respectively). h Secondary colony formation of LL-CBMSC (black boxes) and SL-CBMSC (white boxes) at P4. The differences
were computed by Mann-Whitney U test, p < 0.05. Boxes extend from 25th percentile to the 75th percentile, the middle line represents median value
and the whiskers extend from minimum to maximum values. i Comparison between CB volumes between LL-CBMSC and SL-CBMSC (n= 5 and n= 16,
respectively); the differences were computed by Mann-Whitney U test, p < 0.05. Abbreviations: LL-CBMSC long-living CBMSC, SL-CBMSC short-living
CBMSC, NS not significant
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markers PPARG and FABP4 (p = 0.0547) (Fig. 3i-j).
Immunophenotypic analysis
Immunophenotypic characterization was performed by
flow cytometry in agreement with ISCT criteria. RelevantMSC-related and pericyte markers were investigated
based on current literature [39]. Culture-expanded LL-
CBMSC (n = 5) strongly expressed the MSC markers
CD90, CD105, CD44, CD13, and HLA-ABC, while they
were negative for the hematopoietic markers CD31,







Fig. 3 (See legend on next page.)
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Fig. 3 Multilineage differentiation of CB-MSC. Multilineage ability was determined in P4 LL-CBMSC. a-f Panels display cells which have been
induced to differentiate in vitro toward osteogenic (a-b), adipogenic (c-d), and chondrogenic (e-f) lineages. Osteogenic and adipogenic differentiation were
assessed after 21 days of induction using von Kossa and Oil Red O staining, respectively; ×10 magnification. Chondrogenesis was evaluated by Alcian Blue
staining at day 28 of induction; cells were counterstained with Nuclear Fast Red solution; ×20 magnification. For each staining, undifferentiated controls are
also displayed on the left (panels a-c-e). g Quantitative RT-PCR analysis of osteogenic markers RUNX2 and ALP (g-h), adipogenic markers PPARG and FABP4
(i-j), and chondrogenic markers SOX9 and COLXA1 (k-l) in cells cultured under the respective lineage induction conditions. Results are presented as the fold
change in mRNA expression in respect to TBP as representative reference gene and to the undifferentiated control. The mean values from
three independent experiments done in triplicate are shown. The differences were computed by paired t test or Wilcoxon matched pairs test
as appropriate, p values: **p < 0.01. Abbreviations: NS not significant
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expression, such as the perivascular antigens PDGFRβ,
CD146, and NG2 (Fig. 4a). As already reported by
other authors, CB-MSC were found negative for
CD271 [20, 40]. None of the investigated markers was
found differentially expressed on the surface of LL-
compared to SL-CBMSC (Additional file 10: Fig. S7).
We then evaluated the modifications of MSC immu-
nophenotype after treatment with IFN-γ-1b and TNF-α
for 48 hours, corresponding to induction of immunosup-
pressive function in MSC [5]. As previously demonstrated,
the expression of HLA-ABC, HLA-DR, CD54 (ICAM-1),
and CD106 (VCAM-1) was modulated in the presence
of inflammatory priming [40]. Particularly, significant
upregulation was observed for CD54 (low-negative at rest-
ing conditions) and HLA-ABC (high-positive at resting
conditions) (p = 0.004 and p < 0.001, respectively, Fig. 4
c-d). Upregulation of CD106 (low-negative at resting
conditions) did not reach significance, while the ex-
pression of HLA-DR (negative in resting MSC) was
almost unchanged (Fig. 4b-e).
Immunosuppressive properties of CB-MSC
MSC are known for their remarkable ability to sup-
press the proliferation of several immune cell types
[2]. We tested the immunosuppressive properties of
CB-MSC (specifically LL-CBMSC) by assessing their
capacity to modulate the proliferative response of
CFSE-labeled PBMC upon stimulation with anti-CD3
and rh-IL-2. MSC batches (n = 4) at P5-P6 were ana-
lyzed, provided with additional experiments that there
were no differences in the inhibitory potential with
passaging (e.g., from P2 to P6) on both resting and
primed MSC (Additional file 7: Fig. S4). Flow cytome-
try analysis of CFSE dilution on CD45+ cells showed
that proliferation of activated PBMC was generally
suppressed by MSC in a dose-dependent manner
(Fig. 5a-b). Nevertheless, significant differences in the
inhibitory potential were revealed between individual
MSC batches, particularly after IFN-γ-1b and TNF-α
priming (Fig. 5b). We thus expressed the MSC inhibi-
tory potential in terms of proliferation ratio, as the
ratio between the percentage of CD45+ proliferation
at primed and resting conditions. In most cases, theproliferation ratio increased inversely with MSC dose. For
only one CB-MSC batch, a proliferation ratio directly
increasing with MSC dose was observed, suggesting the
lack of inhibition by inflammatory-primed MSC on PBMC
proliferation (Fig. 5c). In this case, the proliferation ratio
was found significantly greater with respect to other
batches, specifically at 1:0.2 and 1:0.1 PBMC:MSC
ratio (p < 0.001 and p < 0.01, respectively, Fig. 5c).
Discussion
Obtaining definitive data on the effectiveness of MSC in
the clinic is hampered by the lack of standardized
protocols used to prepare large-scale MSC and of useful
tests to compare their potency. Particularly, differences
in donor source, culture methods, and expansion levels
are critical in determining MSC functionality [41, 42].
Our study investigated whether CB may represent a
suitable source of MSC for cell-based therapeutic
strategies. Furthermore, the biological and functional
properties of CB-derived MSC were assessed in view of
a more effective and safer clinical use. By applying
quality criteria for an optimal CB-MSC isolation (CB
volume ≥ 20 ml, time from collection ≤ 24 h), we were
able to isolate MSC colonies from 44% of processed
units. We next evaluated whether isolation was influ-
enced by any clinical features of the donors or CB
parameters, but we found no correlation between the
analyzed parameters and the rate of success in isolating
CB-MSC. Other studies reported isolation yields ranging
from fewer than 10% to 90%, revealing a lack of consen-
sus in the methodological approaches and selection
criteria for CB units [20, 21, 29, 30, 43]. By using DEXA
(10-7 M) as medium supplement in addition to 20% FBS
for 1 week, Zhang et al. achieved a 90% rate of success
in isolating CB-MSC when the volume was ≥ 90 ml and
the time to processing ≤ 2 h [20]. By applying the same
criteria, Pievani et al. were able to obtain MSC from 40%
of processed units only [35].
DEXA was found to inhibit monocyte adhesion, thus
it is conceivable a role of the steroid in supporting the
proliferation of CB-MSC progenitors at the expense of
other contaminants which can adhere on culture plates.
Therefore, its supplementation was applied also in our
study with the aim to promote the adhesion of the rare
Fig. 4 Immunophenotypic analysis of CB-MSC. a Characterization of LL-CBMSC (n = 5) by flow cytometry using a panel of 14 cell surface markers.
Boxes extend from 25th percentile to the 75th percentile, the middle line represents median value and the whiskers extend from minimum to
maximum values. Data are displayed as rMFI on the unstained control. b-e Phenotypic modifications induced on LL-CBMSC (n = 4) by inflammatory
stimuli, i.e., treatment with 10 ng/ml IFN-γ-1b and 15 ng/ml TNF-α for 48 hours before staining with the appropriate mAb combination. Data are
expressed as rMFI with respect to the FMO control. P values <0.05 were considered statistically significant. Abbreviations: rMFI relative median fluorescence
intensity, FMO fluorescence-minus-one, mAb monoclonal antibody
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Fig. 5 Immunosuppressive properties of CB-MSC. a-b Inhibitory
effect of resting (a) and primed (b) LL-CBMSC on allogeneic CFSE-
labeled PBMC. Cells were co-cultured at different PBMC:MSC ratios
upon PBMC stimulation with anti-CD3 and rh-IL-2 for 6 days. Three
different PBMC:MSC ratios were used ranging from 1:0.2 to 1:0.05.
The 1:0 ratio represents the positive control (no MSC treatment and
presence of PBMC antibody stimulation). Proliferation was assessed
by CFSE dilution method on CD45+ cells. Each bar represents mean
and SEM of two independent experiments with two different PBMC
donors for each of four CB-MSC batches. c Proliferation ratio between
the percentage of CD45+ proliferation at primed and resting conditions,
at the different MSC doses. The differences were computed by two-way
ANOVA, **p < 0.01, ***p< 0.001
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and co-workers found no benefit from using alternative
isolation methods or culture conditions, such as immu-
nodepletion before MNC plating, addition of growth
factors to the standard MSC medium, culture in
hypoxia, or coating strategies [20]. Even though the use
of DEXA has been described in the generation of CB-
MSC [20, 34, 35], its dosage varied between investiga-
tors. In the first isolation protocol published by Kögler
et al. [34], DEXA (10-7 M) was added until the detec-
tion of MSC growing colonies, while the expansion was
performed in the absence or at a low concentration of
the supplement. In the present study, the choice to
evaluate two treatment regimens with DEXA was of
particular significance in order to define a standardized
protocol for generating CB-MSC for clinical use. Our
results showed that the extent of DEXA supplementa-
tion did not significantly affect CB culture outcomes, in
regard to both isolation efficiency and long-term prolif-
eration, even if there seemed to be better outcomes in
the group of units treated with DEXA for only 1 week.
Given that culture conditions may have remarkable ef-
fects on the functionality of MSC [33, 44], the addition
of uncommon supplements to standard MSC medium,
like hormones, should be avoided or minimized, at least
when the purpose is to produce MSC with unaltered
stemness properties for clinical use. It should be there-
fore more appropriate and equally effective keeping cell
exposure to DEXA to the minimum required for an
effective CB-MSC isolation.
As discussed, there are some drawbacks linked to the
successful isolation and expansion of CB-MSC, mainly
due to the low frequency of MSC clones in particular
when compared with umbilical cord (UC), a rich source
of high-proliferative MSC characterized by isolation
yields of 100% [45]. To the other hand, UC is a hetero-
geneous tissue whose processing is time-consuming and
labor-intensive in respect to the easier manipulation of
CB. Moreover, public CB banks provide an easy-to-
access system for using freshly donated CB units for
MSC generation, while a similar collection network sys-
tem does not exist for UC or other fetal sources like
placenta. The present study has also revealed that the
role of volume as selection criterion for CB units proc-
essed for CB-MSC isolation should be re-considered
because of affecting neither the rate of successful MSC
isolation nor the growth potential. This finding would
allow to use even CB units of low volume for MSC
isolation.
An important outcome of the present study was to
analyze several in vitro parameters that may help to bet-
ter define the “quality” of CB-derived MSC prior to their
clinical application. The evaluation of the proliferation
capacity as first indicator of MSC potential allowed us to
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[21], who demonstrated the existence of at least two
stromal populations within CB, one long-living (LL-
CBMSC) and the other short-living (SL-CBMSC) on the
basis of their proliferative ability, secondary colony-
forming efficiency and most importantly, telomere
length. The same authors found LL-CBMSC mostly
indiscernible from the SL counterpart in regard to ISCT
criteria [32]. We confirmed that the two MSC popula-
tions clearly diverge in their growth capacity and
secondary colony-forming efficiency, thus suggesting a
potential role of these in vitro parameters as indicators
of CB-MSC longevity. On one hand, the possibility of
cryopreserving low-passage CB-MSC batches in advance
in respect to the clinical needs should allow to monitor
cell growth until the established cPD cutoff, thus render-
ing the retrospective discrimination between LL- and
SL-CBMSC clinically useful. On the other hand, the
evaluation of secondary colony formation may be a
promising and likely early parameter of longevity.
Our data confirmed the absence of major dissimilar-
ities concerning immunophenotype and multilineage
differentiation, fitting both populations the minimal
panel proposed for MSC definition [1]. It is conceivable
that LL-CBMSC represent better candidates for obtain-
ing clinically relevant numbers of MSC for therapeutic
applications, due to the higher ex vivo expansion and
the ability to survive for longer periods in vitro. There-
fore, the assessment of their genetic stability after
prolonged culture represents an important release criter-
ion for a safe clinical use, even if overly expansion
should be avoided too [46, 47].
Unlike MSC from other sources, is widely reported the
relatively low adipogenesis ability of CB-MSC under
standard induction protocols [48–50], most likely due to
their more primordial, fetal origin in respect to other
MSC sources [51]. On the other hand, it is well docu-
mented that there is more propensity toward chondrogen-
esis and osteogenesis in vitro under appropriate culture
conditions and to some extent in vivo [20, 35, 52, 53].
Sacchetti and co-workers [53] have recently demonstrated
a unique capacity of CB-derived stromal cells to form
cartilage in vivo spontaneously, in addition to an osteo-
genic capacity. Therefore, they support the presence
within CB of chondro-osteoprogenitors rather than multi-
potent MSC, whose origin, however, remains to be eluci-
dated. Our data confirmed an impaired adipogenic
potential of CB-MSC, revealed by a clear absence of cells
forming lipid droplets and confirmed at a molecular level
by the absence of significant mRNA induction of PPARG
and FABP4, the former representing a crucial player
during the transcriptional cascade leading to adipogenic
differentiation, the latter being its direct target. More in
general, our molecular analysis highlighted a widevariability in the differentiation potential between individ-
ual samples. This finding may fit the increasing evidence
of the existence of distinct CB-derived stromal progeni-
tors, possibly of different developmental origin and related
plasticity [53–56]. In this regard, unrestricted somatic
stromal cells (USSC) and cord blood-derived stromal cells
(CB-MSC) were originally defined according to the ex-
pression of the adipogenic inhibitor delta-like 1 (DLK-1), a
specific marker of USSC correlating with a lack of adipo-
genic differentiation ability and a higher proliferative po-
tential compared to the more differentiated and less
proliferative CB-MSC [54]. Even if in our experience
a lack of adipogenic potential was common to both
LL- and SL-CBMSC, it remains unclear whether the
more immature USSC match our LL-CBMSC.
The ultimate aim of the present work was to investi-
gate the immunosuppressive activity of both resting and
inflammatory-primed CB-MSC, in order to complete
their functional characterization prior to clinical applica-
tion. Despite the recent suggestions provided by ISCT
[37, 42, 57], a universally accepted in vitro method to as-
sess MSC immunosuppression does not exist [58, 59].
We used unselected and opportunely stimulated PBMC
because more closely mimic the in vivo inflammatory
environment to which MSC are exposed on patient
administration. Our results showed that CB-MSC inhib-
ited PBMC proliferation with different efficacy, particu-
larly after treatment with exogenous IFN-γ-1b and TNF-α.
The lack of efficacy of one batch was found despite the
flow cytometry upregulation of priming-inducible markers.
Moreover, it was confirmed repeatedly on different PBMC
donors. In this situation, a trophic effect mediated by
primed CB-MSC was conceivable on PBMC proliferation.
Additional studies would be warranted to determine how
correlating this observation with other immunomodula-
tory markers, for adequately predicting the in vivo
potency of CB-MSC. von Bahr and co-authors [60]
reported no evidence of correlation between the
in vitro inhibitory potential of MSC and in vivo clinical
response in patients with aGvHD, suggesting that the
in vivo efficacy of MSC not only depends on the in-
trinsic properties of the MSC preparation but also on
the product-host interaction. A detailed immunomoni-
toring of patients as well as an in-depth characterization
of MSC would therefore be helpful to correlate the
in vitro measure of the potency with clinical out-
comes [61].
Conclusions
In summary, the present work shows that CB may be a
practical source of MSC for clinical applications. CB
remains much more readily available and devoid of
major ethical concerns in respect to other conventional
MSC sources. To the best of our knowledge, we have
Amati et al. Stem Cell Research & Therapy  (2017) 8:14 Page 13 of 15provided evidence that not all LL-CBMSC are equally
immunosuppressive in an inflammatory environment,
in support of the need to include the assessment of
in vitro potency among the release criteria for each
CB-MSC batch intended for clinical use, at least for the
treatment of immune disorders such as GvHD.
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